In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), all of which express mutant KRAS (Table S2). This evidence concerns the gene KRAS and colorectal carcinoma.